NCT00392171View on ClinicalTrials.gov

The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 9, 2006

Primary Completion Date

September 15, 2009

Study Completion Date

September 15, 2009

Conditions
GliomaAstrocytomaOligodendrogliomaGlioblastoma
Interventions
DRUG

Temozolomide

Subjects will receive temozolomide 50 mg/m\^2 for cycles of 28 days for 12 months or until progression

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00392171 - The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | Biotech Hunter | Biotech Hunter